1.Investigation and optimization strategies for pharmaceutical care needs of the elderly in community based on the Kano model
Xianzhen ZHENG ; Tengqi YANG ; Li CHEN ; Quyue WANG ; Zonghui WU ; Li YOU
China Pharmacy 2025;36(16):2057-2061
OBJECTIVE To investigate and analyze the pharmaceutical care needs of the elderly, thus providing a reference for improving the pharmaceutical care for the elderly. METHODS Based on the Kano model, a questionnaire was designed, and 1 200 community-dwelling elderly in the main urban area of Chongqing were selected as the survey subjects. The study analyzed the attributes and urgency of their pharmaceutical care needs to put forward optimization strategies. RESULTS A total of 1 200 questionnaires were distributed in the study, and 1 062 valid questionnaires were collected, with an effective response rate of 88.50%. The gender distribution of respondents was relatively balanced, with the majority aged between 60 and 69 (43.41%), and generally possessing a relatively low level of educational attainment. The results showed that medication education and medication consultation were must-be needs; home-based pharmaceutical care was an expected need; drug reorganization, medication monitoring, pharmaceutical science popularization, and pharmaceutical ward round were attractive needs; internet-based pharmaceutical care was indifferent need. The urgent order of demand was medication education > medication consultation > home-based pharmaceutical care > pharmaceutical science popularization > drug reorganization > medication monitoring > pharmaceutical ward round > internet-based pharmaceutical care. CONCLUSIONS The community elderly in Chongqing have high expectations for pharmaceutical care as a whole. Medical institutions should fully guarantee the two essential needs of medication education and medication consultation, and focus on ensuring the expected needs for home-based pharmaceutical care. Efforts should be made to develop the four attractive needs of pharmaceutical science popularization, drug reorganization, medication monitoring, and pharmaceutical ward round, and actively carry out age-friendly adaptations for internet-based pharmaceutical care.
2.Analysis of the clinical efficacy-value of electroacupuncture manipulation and massage therapy in the treatment of knee osteoarthritis
Xianzhen WEI ; Haiyun WANG ; Yishan DING ; Chaowei CHEN
China Modern Doctor 2025;63(5):39-41,52
Objective To observe the clinical efficacy of electroacupuncture manipulation combined with massage therapy in the treatment of knee osteoarthritis,and to analyze the efficacy-value.Methods A total of 118 patients with knee osteoarthritis admitted to Kuitun Traditional Chinese Medicine Hospital of Xinjiang Production and Construction Corps from January 2023 to January 2024 were selected as research subjects and divided into electroacupuncture manipulation and massage group(n=60)and sodium hyaluronate group(n=58)by random number table methood.Electroacupuncture manipulation and massage group was treated 3 times a week for 3 weeks.Sodium hyaluronate group was injected with sodium hyaluronate injection in the joint cavity once a week for 3 weeks.Knee function scores and effective rate of two groups before and after treatment were observed,and the differences between two treatments were compared by using the health economics evaluation method.Results After comparing the patients before and after treatment,the knee function scores improved.There was significant difference of knee function scores after treatment between two groups(P<0.05).There were significant difference of response rate and the incidence of adverse effects between two groups(P<0.05).Sodium hyaluronate group had a better clinical efficacy-value than electroacupuncture manipulation and massage group.Conclusion Electroacupuncture manipulation and massage and sodium hyaluronate intra-articular injection can effectively improve joint pain and joint function in patients,and intra-articular injection of sodium hyaluronate has a higher incidence of adverse reactions.
3.Impact of diagnosis-intervention packet implementation on hospitalization costs for patients with lung malignancies
Xin LI ; Dan XU ; Xianzhen CHEN ; Yingying WANG ; Tingting YANG ; Yanfei GAO ; Haojie XIE
Chinese Journal of Hospital Administration 2025;41(2):157-164
Objective:To analyze the changes and structural variations in hospitalization costs for patients with lung malignancies after the implementation of diagnosis-intervention packet (DIP) payment system, and to evaluate its effectiveness.Methods:Data from the first page of medical records and hospitalization cost data from the hospital information system of a tertiary general hospital in Henan Province were extracted for patients diagnosed with lung malignancies from 2020 to 2023. The data were divided into pre-implementation group (2020—2021) and post-implementation group (2022—2023) based on the implementation time of DIP. Chi-square test, t test, and Wilcoxon rank-sum test were used to analyze the differences in basic characteristics and hospitalization costs of patients with lung malignancies before and after the implementation of DIP. Grey relational analysis was employed to examine the internal associations between total hospitalization costs and various cost components. Structural variation analysis was used to assess the changes in the structure of hospitalization costs after the implementation of DIP. Results:A total of 14 587 hospitalized patients with lung malignancies were included, with 6 807 cases in the pre-implementation group and 7 780 cases in the post-implementation group. The average length of hospital stay decreased from (13.17±6.74) days before implementation to (12.02±6.49) days after implementation ( P<0.05). The proportion of level-four surgeries increased from 46.4% to 57.0% ( P<0.05). The average hospitalization cost per patient with lung malignancies decreased from 56 952 yuan before DIP implementation to 55 560 yuan after implementation ( P<0.05). For patients with lung malignancies diagnosed as C34.1, C34.2, C34.3, and C34.8, the top four cost components most strongly associated with total hospitalization costs were treatment costs, material costs, comprehensive medical service costs, and diagnostic costs, with correlation coefficients all>0.80. For patients with C34.9, the top four cost components most strongly associated with total hospitalization costs were treatment costs, comprehensive medical service costs, diagnostic costs, and Western medicine costs, with correlation coefficients>0.95. For patients diagnosed as C34.1, C34.2, C34.3, and C34.9, diagnostic costs, Western medicine costs, and material costs contributed significantly to the structural variation of hospitalization costs, with contribution rate of structure variation all exceeding 75%, among which Western medicine costs and material costs showed negative variation. For patients diagnosed as C34.8, treatment costs, Western medicine costs, and material costs contributed significantly to the structural variation of hospitalization costs, with contribution rate of structure variation all exceeding 80%, among which Western medicine costs showed negative variation. Conclusions:The implementation of DIP reduced the hospitalization costs for patients with lung malignancies, optimized the structure of hospitalization costs, improved the efficiency of medical services, and promoted the rational allocation of medical resources.
4.Analysis of the Effects of Tongfu Xiefei Formula on Serum Inflammatory Cytokines in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease Based on the Theory of Simultaneous Treatment of Lung and Intestine
Guoqing ZHU ; Yan ZHOU ; Xianzhen LI ; Lili TANG ; He CHEN ; Zhiliang LIU
Journal of Guangzhou University of Traditional Chinese Medicine 2025;42(6):1340-1348
Objective To investigate the clinical efficacy of Tongfu Xiefei Formula in treating patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)based on the theory of simultaneous treatment of lung and intestine,and to observe its effects on serum inflammatory cytokines.Methods A retrospective study was conducted on 134 AECOPD patients treated at the Department of Pulmonary Diseases of Traditional Chinese Medicine,Tangshan Hospital of Traditional Chinese Medicine from December 2020 to December 2022.The patients were divided into an observation group and a western medicine group based on the treatment plans,with 67 cases in each group.The western medicine group received conventional western medical treatment,while the observation group was given Tongfu Xiefei Formula orally in addition to the western medical treatment.The course of treatment covered 2 weeks.Before and after treatment,the two groups were observed in the changes of the modified Medical Research Council(mMRC)dyspnea scale scores,COPD Assessment Test(CAT)scores,lung function indicators,arterial blood gas analysis indicators,and serum inflammatory cytokine levels.The clinical efficacy,total incidence of adverse reactions,and hospitalization time were compared between the two groups.Results(1)After 2 weeks of treatment,the total effective rate in the observation group was 95.52%(64/67),compared to 79.10%(53/67)in the western medicine group.The intergroup comparison(tested by the chi-square test)showed that the efficacy of the observation group was significantly superior to that of the western medicine group(P<0.01).(2)After treatment,the mMRC scores and CAT scores in both groups were significantly decreased(P<0.05),and the decrease in the observation group was significantly superior to that in the western medicine group(P<0.01).(3)After treatment,lung function indicators of the forced expiratory volume in one second(FEV1),forced vital capacity(FVC),and their ratio(FEV1/FVC)in both groups were significantly increased(P<0.05),and the increase in the observation group was significantly superior to that in the western medicine group(P<0.01).(4)After treatment,the oxygen saturation(SaO2)and arterial oxygen partial pressure(PaO2)levels in both groups significantly increased(P<0.05),while the arterial carbon dioxide partial pressure(PaCO2)level was significantly decreased(P<0.05).The increase in SaO2 and PaO2 levels and the decrease in PaCO2 level in the observation group were significantly superior to those in the western medicine group(P<0.01).(5)After treatment,the levels of serum inflammatory cytokines of tumor necrosis factor α(TNF-α),C-reactive protein(CRP),and interleukin-6(IL-6)in both groups were significantly decreased(P<0.05),and the decrease in the observation group was significantly superior to that in the western medicine group(P<0.01).(6)The total incidence of adverse reactions in the observation group was 2.99%(2/67),compared to 5.97%(4/67)in the western medicine group,with no statistically significant difference between the two groups(P>0.05).(7)The observation group had a significantly shorter hospitalization time than the western medicine group,and the difference was statistically significant(P<0.05).Conclusion Tongfu Xiefei Formula,formulated based on theory of simultaneous treatment of lung and intestine,is effective and safe on relieving symptoms such as dyspnea in AECOPD patients,improving lung function,correcting arterial blood gas disorders,inhibiting the release of inflammatory factors,shortening treatment time,while causing no serious adverse reactions.
5.An observational study on efficacy and safety of regimens containing delamanid and linezolid in the treatment of rifampicin resistant tuberculosis for 24 weeks
Liping ZOU ; Qing CHEN ; Zhengyu SHI ; Xianzhen TANG ; Li LIANG ; Lei CHEN ; Guihui WU
Chinese Journal of Infection and Chemotherapy 2025;25(5):498-504
Objective To evaluate the early efficacy and safety of the regimens containing delamanid and linezolid in the treatment of rifampicin resistant tuberculosis(RR-TB).Methods A total of 47 patients diagnosed with RR-TB at Public Health Clinical Center of Chengdu from August 2020 to December 2021 were enrolled,including 22 cases(46.8%)of multidrug-resistant tuberculosis(MDR-TB),8 cases(17.0%)of RR-TB,and 17 cases(36.2%)of pre-extensively drug-resistant tuberculosis(pre-XDR-TB).All patients were treated with a regimen based on delamanid and linezolid.The efficacy and safety were evaluated at 24 weeks of treatment.Results Among the 47 patients,46(97.9%)completed 24 weeks of treatment and 1(2.1%)was lost to follow-up.At 24 weeks,the sputum culture conversion rate was 100%in the 43 patients with positive baseline sputum culture.The median conversion time was 2(2,8)weeks.Imaging examination showed absorption in 46 patients(97.9%).Overall,40 patients(85.1%)experienced varying degrees of adverse events(AEs)within 24 weeks.Eleven patients(23.4%)experienced AEs possibly related to delamanid,mainly including QTcF interval prolongation(12.8%),gastrointestinal reactions(8.5%),dizziness(2.1%),headache(2.1%),and allergy(2.1%).Six patients permanently discontinued delamanid due to AEs including gastrointestinal reactions(6.4%),prolonged QTcF interval(2.1%),severe dizziness(2.1%),and drug allergy(2.1%).Patients with low baseline CD4+T lymphocyte counts(OR=0.991,95%CI:0.984-0.999)were more likely to experience delamanid-related AEs.Thirty patients(63.8%)experienced AEs possibly related to linezolid,including myelosuppression(55.3%),peripheral neuropathy(6.4%),optic neuritis occurred(2.1%),and allergy(2.1%).Three patients(6.4%)discontinued linezolid permanently due to severe anemia,peripheral neuropathy,and allergy.Conclusions The treatment regimens containing delamanid and linezolid for RR-TB showed a high sputum culture conversion rate and good tolerance at 24 weeks.Attention should be paid to gastrointestinal reactions and cellular immunity during treatment.
6.An observational study on efficacy and safety of regimens containing delamanid and linezolid in the treatment of rifampicin resistant tuberculosis for 24 weeks
Liping ZOU ; Qing CHEN ; Zhengyu SHI ; Xianzhen TANG ; Li LIANG ; Lei CHEN ; Guihui WU
Chinese Journal of Infection and Chemotherapy 2025;25(5):498-504
Objective To evaluate the early efficacy and safety of the regimens containing delamanid and linezolid in the treatment of rifampicin resistant tuberculosis(RR-TB).Methods A total of 47 patients diagnosed with RR-TB at Public Health Clinical Center of Chengdu from August 2020 to December 2021 were enrolled,including 22 cases(46.8%)of multidrug-resistant tuberculosis(MDR-TB),8 cases(17.0%)of RR-TB,and 17 cases(36.2%)of pre-extensively drug-resistant tuberculosis(pre-XDR-TB).All patients were treated with a regimen based on delamanid and linezolid.The efficacy and safety were evaluated at 24 weeks of treatment.Results Among the 47 patients,46(97.9%)completed 24 weeks of treatment and 1(2.1%)was lost to follow-up.At 24 weeks,the sputum culture conversion rate was 100%in the 43 patients with positive baseline sputum culture.The median conversion time was 2(2,8)weeks.Imaging examination showed absorption in 46 patients(97.9%).Overall,40 patients(85.1%)experienced varying degrees of adverse events(AEs)within 24 weeks.Eleven patients(23.4%)experienced AEs possibly related to delamanid,mainly including QTcF interval prolongation(12.8%),gastrointestinal reactions(8.5%),dizziness(2.1%),headache(2.1%),and allergy(2.1%).Six patients permanently discontinued delamanid due to AEs including gastrointestinal reactions(6.4%),prolonged QTcF interval(2.1%),severe dizziness(2.1%),and drug allergy(2.1%).Patients with low baseline CD4+T lymphocyte counts(OR=0.991,95%CI:0.984-0.999)were more likely to experience delamanid-related AEs.Thirty patients(63.8%)experienced AEs possibly related to linezolid,including myelosuppression(55.3%),peripheral neuropathy(6.4%),optic neuritis occurred(2.1%),and allergy(2.1%).Three patients(6.4%)discontinued linezolid permanently due to severe anemia,peripheral neuropathy,and allergy.Conclusions The treatment regimens containing delamanid and linezolid for RR-TB showed a high sputum culture conversion rate and good tolerance at 24 weeks.Attention should be paid to gastrointestinal reactions and cellular immunity during treatment.
7.Analysis of the clinical efficacy-value of electroacupuncture manipulation and massage therapy in the treatment of knee osteoarthritis
Xianzhen WEI ; Haiyun WANG ; Yishan DING ; Chaowei CHEN
China Modern Doctor 2025;63(5):39-41,52
Objective To observe the clinical efficacy of electroacupuncture manipulation combined with massage therapy in the treatment of knee osteoarthritis,and to analyze the efficacy-value.Methods A total of 118 patients with knee osteoarthritis admitted to Kuitun Traditional Chinese Medicine Hospital of Xinjiang Production and Construction Corps from January 2023 to January 2024 were selected as research subjects and divided into electroacupuncture manipulation and massage group(n=60)and sodium hyaluronate group(n=58)by random number table methood.Electroacupuncture manipulation and massage group was treated 3 times a week for 3 weeks.Sodium hyaluronate group was injected with sodium hyaluronate injection in the joint cavity once a week for 3 weeks.Knee function scores and effective rate of two groups before and after treatment were observed,and the differences between two treatments were compared by using the health economics evaluation method.Results After comparing the patients before and after treatment,the knee function scores improved.There was significant difference of knee function scores after treatment between two groups(P<0.05).There were significant difference of response rate and the incidence of adverse effects between two groups(P<0.05).Sodium hyaluronate group had a better clinical efficacy-value than electroacupuncture manipulation and massage group.Conclusion Electroacupuncture manipulation and massage and sodium hyaluronate intra-articular injection can effectively improve joint pain and joint function in patients,and intra-articular injection of sodium hyaluronate has a higher incidence of adverse reactions.
8.Impact of diagnosis-intervention packet implementation on hospitalization costs for patients with lung malignancies
Xin LI ; Dan XU ; Xianzhen CHEN ; Yingying WANG ; Tingting YANG ; Yanfei GAO ; Haojie XIE
Chinese Journal of Hospital Administration 2025;41(2):157-164
Objective:To analyze the changes and structural variations in hospitalization costs for patients with lung malignancies after the implementation of diagnosis-intervention packet (DIP) payment system, and to evaluate its effectiveness.Methods:Data from the first page of medical records and hospitalization cost data from the hospital information system of a tertiary general hospital in Henan Province were extracted for patients diagnosed with lung malignancies from 2020 to 2023. The data were divided into pre-implementation group (2020—2021) and post-implementation group (2022—2023) based on the implementation time of DIP. Chi-square test, t test, and Wilcoxon rank-sum test were used to analyze the differences in basic characteristics and hospitalization costs of patients with lung malignancies before and after the implementation of DIP. Grey relational analysis was employed to examine the internal associations between total hospitalization costs and various cost components. Structural variation analysis was used to assess the changes in the structure of hospitalization costs after the implementation of DIP. Results:A total of 14 587 hospitalized patients with lung malignancies were included, with 6 807 cases in the pre-implementation group and 7 780 cases in the post-implementation group. The average length of hospital stay decreased from (13.17±6.74) days before implementation to (12.02±6.49) days after implementation ( P<0.05). The proportion of level-four surgeries increased from 46.4% to 57.0% ( P<0.05). The average hospitalization cost per patient with lung malignancies decreased from 56 952 yuan before DIP implementation to 55 560 yuan after implementation ( P<0.05). For patients with lung malignancies diagnosed as C34.1, C34.2, C34.3, and C34.8, the top four cost components most strongly associated with total hospitalization costs were treatment costs, material costs, comprehensive medical service costs, and diagnostic costs, with correlation coefficients all>0.80. For patients with C34.9, the top four cost components most strongly associated with total hospitalization costs were treatment costs, comprehensive medical service costs, diagnostic costs, and Western medicine costs, with correlation coefficients>0.95. For patients diagnosed as C34.1, C34.2, C34.3, and C34.9, diagnostic costs, Western medicine costs, and material costs contributed significantly to the structural variation of hospitalization costs, with contribution rate of structure variation all exceeding 75%, among which Western medicine costs and material costs showed negative variation. For patients diagnosed as C34.8, treatment costs, Western medicine costs, and material costs contributed significantly to the structural variation of hospitalization costs, with contribution rate of structure variation all exceeding 80%, among which Western medicine costs showed negative variation. Conclusions:The implementation of DIP reduced the hospitalization costs for patients with lung malignancies, optimized the structure of hospitalization costs, improved the efficiency of medical services, and promoted the rational allocation of medical resources.
9.Clinical characteristics and risk factors of MDRRR-TB patients with decreased peripheral blood CD4+T lymphocytes
ZUO Liping, ; CHEN Qing, ; XIAN Xianzhen
China Tropical Medicine 2024;24(5):537-
Abstract: Objective To explore clinical characteristics and the related factors of multidrug-resistant tuberculosis and rifampicin-resistant tuberculosis (MDR/RR-TB) patients with decreased peripheral blood CD4+T lymphocytes, providing a basis for the prevention and treatment of multidrug-resistant tuberculosis. Methods A retrospective analysis was conducted on 311 MDR/RR-TB patients hospitalized at Chengdu Public Health Clinical Center from January 2018 to December 2020. according to whether accompanied by peripheral blood CD4+T lymphocyte reduction, patients were divided into two groups, the decreased group (n=115) with CD4+T lymphocytes count <414 cell/μL and the normal group (n=196) with CD4+T lymphocytes count ≥ 414 cell/μL. Clinic data, including demographics, types of tuberculosis, complications, clinical symptoms, chest imaging, and treatment outcomes were collected. The binary logistic regression equation was used to analyze the risk factors of MDR/RR-TB with peripheral blood CD4+T lymphocyte reduction. Results In total, 311 cases with MDR/RR-TB were enrolled, with a male-to-female ratio of 1.68∶1. The median age [M(P25, P75)] was 32 (24, 45) years. The median CD4+T lymphocyte count was 492.0 (328.0, 661.0) cells/μL, and 115 patients had CD4+T lymphocyte counts <414 cells/μL. Compared with the normal group, the proportion of older patients, male, baseline anemia, baseline leukopenia, baseline hypoalbuminemia, combined with other chronic respiratory diseases, hematogenous disseminated pulmonary tuberculosis, tuberculous pleurisy, and tuberculous meningitis were higher (P<0.05), while the success rate of treatment was lower in the decreased group (P=0.024). Being male (OR=2.045, 95%CI : 1.147-3.648), older age (OR=1.032, 95%CI : 1.012-1.052), baseline anemia (OR=2.246, 5%CI : 1.457-3.426), and baseline leukopenia (OR=2.398, 95%CI : 1.387-4.148) were risk factors for decreased CD4+T lymphocyte count in MDR/RR-TB patients. Conclusions MDR/RR-TB patients with decreased CD4+T lymphocytes are more likely to suffer from severe tuberculosis (hematogenic disseminated tuberculosis, tuberculous meningitis) and tuberculous pleurisy, meanwhile the success rate of treatment was lower. Male, elder age, baseline anemia, and baseline leukopenia are associated with decreased CD4+T lymphocyte count in MDR/RR-TB patients, and the immune status of these patients needs to be paid attention to in clinical work.
10.Analysis of influencing factors for multidrug-resistant pulmonary tuberculosis in Hainan Province from 2014 to 2020
CHEN Shanying ; LIU Rui ; ZHANG Fuwei ; CHEN Xianzhen ; LIU Peiyun ; HE Jing
China Tropical Medicine 2023;23(8):852-
Abstract: Objective To investigate the occurrence of multidrug-resistance among tuberculosis patients in Hainan Province from 2014 to 2020 and to analyze the influencing factors, aiming to provide reference for formulating drug-resistant tuberculosis control strategies in this region. Methods This study collected sputum samples from the patients with pulmonary tuberculosis admitted to the Second Affiliated Hospital of Hainan Medical University from 2014 to 2020, and performed
isolation and identification of Mycobacterium tuberculosis and drug susceptibility testing. After the strains were identified as positive, drug sensitivity tests were conducted, and multi-drug resistant patients were found. Clinical data was retrospectively collected, and chi-square test and unconditioned logistic regression were used to analyze the influencing factors of multidrug resistance. Results A total of 2 672 patients underwent sputum culture, strain identification, and drug susceptibility testing in TB designated hospitals in Hainan Province from January 1, 2014 to December 31, 2020. Among them, 1 942 patients with available drug susceptibility test results and complete clinical data were enrolled, among which 398 cases with drug-resistant TB were included in the case group, and 1 544 cases without drug resistance were included in the control group. Multivariate logistic regression analysis showed that farmers, rural residence, treatment history of retreatment, irregular medication history, number of pulmonary cavities ≥3, and BMI<18.5 were independent risk factors for MDR-TB. The risk of MDR-TB in farmers was higher than that in non-farmers (OR=1.542, 95%CI: 1.150-2.020); patients living in rural areas had a higher risk of multidrug resistance than those living in urban areas (OR=1.445, 95%CI: 1.095-1.907); the risk of MDR in the retreatment patients was higher than that in the initial treatment patients (OR=5.616, 95%CI: 4.250-7.421); the risk of multi-drug resistance in patients with irregular medication was higher than that in patients with regular medication (OR=2.665, 95%CI: 2.012-3.531); the risk of multidrug resistance in patients with pulmonary cavity number ≥3 was higher than that in patients with pulmonary cavity number <3 (OR=5.040, 95%CI: 3.768-6.740); compared with patients with BMI<18.5, patients with BMI=18.5-24.0 and BMI≥24.0 had a lower risk of multidrug resistance (OR=0.735, 95%CI: 0.555-0.975 and OR=0.447,95%CI:0.225-0.888, respectively). Conclusions Retreatment, farmer occupation, rural residence, irregular medication and low BMI may be the risk factors for multidrug resistance in Hainan Province.

Result Analysis
Print
Save
E-mail